Sign in to view content

Results From Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity

Rishi P. Singh, MD

Video
Published 2024

Related

Debate: How Should We Treat Geographic Atrophy
Ajay E Kuriyan, MD, MS
Updates from the Field
2024
Episode 199: Nov/Dec 2019 Retinal Physician Preview: New Pathways for Dry AMD
Jayanth Sridhar, MD
Member Podcasts
2019
Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021

Category: AMD-Non-Neovascular

See more